Pharmacogenetic screening of carbamazepine-induced severe cutaneous allergic reactions

Locharernkul, Chaichon; Shotelersuk, Vorasuk; Hirankarn, Nattiya

doi:10.1016/j.jocn.2010.12.054

Cited by 40 publications

(48 citation statements)

References 46 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They should be advised to contact the treating physician if they observe any type of skin rashes or mucosal ulcers as they require urgent medical evaluation to determine the nature of rashes/ulcers and implementation of most appropriate treatment options which might include discontinuation of these medications and instituting other therapeutic strategies to treat serious rashes and prevent destabilization of BD. Further, prior to commencing carbamazepine, patients with ancestry in genetically at‐risk populations such as Han Chinese and other Asian patients should have genotyping performed to ensure that they do not have the human leucocyte antigen (HLA)‐B*1502 allele, which confers a high risk for SJS/TEN with carbamazepine 800. In addition, those on carbamazepine therapy should have serum sodium levels measured at least annually and as clinically indicated given the risk of hyponatraemia with this compound.…”

Section: Safety and Monitoringmentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

et al. 2018

View full text Add to dashboard Cite

The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published treatment guidelines for bipolar disorder in 2005, along with international commentaries and subsequent updates in 2007, 2009, and 2013. The last two updates were published in collaboration with the International Society for Bipolar Disorders (ISBD). These 2018 CANMAT and ISBD Bipolar Treatment Guidelines represent the significant advances in the field since the last full edition was published in 2005, including updates to diagnosis and management as well as new research into pharmacological and psychological treatments. These advances have been translated into clear and easy to use recommendations for first, second, and third‐ line treatments, with consideration given to levels of evidence for efficacy, clinical support based on experience, and consensus ratings of safety, tolerability, and treatment‐emergent switch risk. New to these guidelines, hierarchical rankings were created for first and second‐ line treatments recommended for acute mania, acute depression, and maintenance treatment in bipolar I disorder. Created by considering the impact of each treatment across all phases of illness, this hierarchy will further assist clinicians in making evidence‐based treatment decisions. Lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone, and cariprazine alone or in combination are recommended as first‐line treatments for acute mania. First‐line options for bipolar I depression include quetiapine, lurasidone plus lithium or divalproex, lithium, lamotrigine, lurasidone, or adjunctive lamotrigine. While medications that have been shown to be effective for the acute phase should generally be continued for the maintenance phase in bipolar I disorder, there are some exceptions (such as with antidepressants); and available data suggest that lithium, quetiapine, divalproex, lamotrigine, asenapine, and aripiprazole monotherapy or combination treatments should be considered first‐line for those initiating or switching treatment during the maintenance phase. In addition to addressing issues in bipolar I disorder, these guidelines also provide an overview of, and recommendations for, clinical management of bipolar II disorder, as well as advice on specific populations, such as women at various stages of the reproductive cycle, children and adolescents, and older adults. There are also discussions on the impact of specific psychiatric and medical comorbidities such as substance use, anxiety, and metabolic disorders. Finally, an overview of issues related to safety and monitoring is provided. The CANMAT and ISBD groups hope that these guidelines become a valuable tool for practitioners across the globe.

show abstract

Section: Safety and Monitoringmentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Concerning genetic screening, in the case of HLA-B*15:02, a retrospective study performed in Thailand concluded that screening for this allele is less costly than treating carbamazepine-induced SJS cases [77]. However, according to the US Food and Drug Administration, screening for HLA-B*15:02 is only recommended for patients of Asian ancestry, since this allele is mainly expressed in those individuals [62].…”

Section: Carbamazepinementioning

confidence: 99%

HLA and Delayed Drug-Induced Hypersensitivity

Sousa‐Pinto¹,

Correia²,

Gomes³

et al. 2016

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Delayed drug allergy reactions (DDAR) are potentially fatal. Certain human leukocyte antigen (HLA) alleles have been associated with delayed allergy reactions following the administration of particular drugs. Examples are HLA-B*57:01 (abacavir), HLA-B*15:02/HLA-A*31:01 (carbamazepine), and HLA-B*58:01 (allopurinol). Based on the identification of these associations, it may now be possible to prevent certain allergy reactions that were, until recently, considered unpredictable. In this review, we will focus on the pharmacogenetics of the best-studied associations between specific HLA alleles and delayed allergy reactions and describe the pathogenesis models proposed so far. Finally, we will evaluate the genetic screening strategies available and discuss the clinical relevance of a better understanding of the immunogenetics and mechanisms involved in DDAR.

show abstract

“…Cette association n'a pas été retrouvée en Corée, au Japon et chez les caucasiens 7,14,18 . 7,19 . Dans le cas où le dépistage de l'allèle est utilisé comme marqueur pour prévenir un SSJ/NET induit par la CBZ, la valeur prédictive négative et la sensibilité du test sont respectivement estimées à 98 % et à 92 % 7,19 .…”

Section: Key Pointsunclassified

“…7,19 . Dans le cas où le dépistage de l'allèle est utilisé comme marqueur pour prévenir un SSJ/NET induit par la CBZ, la valeur prédictive négative et la sensibilité du test sont respectivement estimées à 98 % et à 92 % 7,19 . Le pourcentage de faux positifs varie entre 4,2 % et 19 % 7,19 .…”

Section: Key Pointsunclassified

“…Deuxièmement, dans les cas moins urgents, il peut être envisagé de retarder le début de la CBZ jusqu'à l' obtention du résultat du test. Somme toute, l'accessibilité au test demeure le principal enjeu et il serait souhaitable qu'il soit universellement disponible afin d' obtenir le résultat dans les plus brefs délais 7,19 . Le rapport coût-efficacité du test de dépistage du HLA-B*1502 doit être considéré.…”

Section: Key Pointsunclassified

See 1 more Smart Citation

Nécrolyse épidermique toxique induite par la carbamazépine chez une Cambodgienne

et al. 2013

View full text Add to dashboard Cite

Pharmacogenetic screening of carbamazepine-induced severe cutaneous allergic reactions

Cited by 40 publications

References 46 publications

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

HLA and Delayed Drug-Induced Hypersensitivity

Nécrolyse épidermique toxique induite par la carbamazépine chez une Cambodgienne

Contact Info

Product

Resources

About